Your browser is no longer supported. Please, upgrade your browser.
APHB AmpliPhi Biosciences Corporation monthly Stock Chart
APHB [NYSE]
AmpliPhi Biosciences Corporation
Index- P/E- EPS (ttm)-0.75 Insider Own4.80% Shs Outstand24.57M Perf Week-52.57%
Market Cap7.92M Forward P/E- EPS next Y-0.79 Insider Trans0.00% Shs Float16.06M Perf Month-67.26%
Income-9.30M PEG- EPS next Q-0.21 Inst Own10.90% Short Float8.92% Perf Quarter-70.41%
Sales0.06M P/S136.62 EPS this Y91.90% Inst Trans- Short Ratio3.45 Perf Half Y-72.90%
Book/sh0.51 P/B0.63 EPS next Y9.20% ROA-73.00% Target Price6.00 Perf Year-73.13%
Cash/sh0.24 P/C1.37 EPS next 5Y- ROE-100.40% 52W Range0.32 - 2.05 Perf YTD-68.07%
Dividend- P/FCF- EPS past 5Y46.10% ROI-192.90% 52W High-84.27% Beta1.87
Dividend %- Quick Ratio3.00 Sales past 5Y-29.60% Gross Margin- 52W Low2.02% ATR0.11
Employees31 Current Ratio3.00 Sales Q/Q- Oper. Margin- RSI (14)20.07 Volatility17.43% 14.99%
OptionableNo Debt/Eq0.00 EPS Q/Q84.70% Profit Margin- Rel Volume2.14 Prev Close0.33
ShortableNo LT Debt/Eq0.00 EarningsNov 08 AMC Payout- Avg Volume414.89K Price0.32
Recom2.00 SMA20-62.55% SMA50-66.62% SMA200-71.58% Volume889,196 Change-1.13%
Jan-17-18Reiterated H.C. Wainwright Buy $5 → $6
Aug-28-17Initiated H.C. Wainwright Buy $5
Oct-16-18 04:10PM  AmpliPhi Biosciences Announces Closing of Public Offering Business Wire
Oct-12-18 06:00AM  AmpliPhi Biosciences Announces Pricing of $6.6 Million Underwritten Public Offering Business Wire -32.79%
Oct-08-18 06:50AM  AmpliPhi Biosciences Announces Presentation of Positive Clinical Data From its Expanded Access Program for Serious S. aureus Infections at IDWeek 2018 Conference Business Wire -9.65%
Sep-27-18 09:45AM  APHB: Continued Success for Expanded Access Program; Ready to Initiate Clinical Trials for AB-SA01 Zacks Small Cap Research +5.15%
Sep-24-18 06:50AM  AmpliPhi Biosciences to Present Clinical Case Series Data at IDWeek 2018 Business Wire +11.12%
Sep-18-18 08:00AM  AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-PA01 Targeting Pseudomonas Aeruginosa Infections Business Wire -11.68%
Sep-17-18 09:00AM  AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-SA01 Business Wire
08:00AM  AmpliPhi Biosciences Announces Updated Positive Clinical Results for its Expanded Access Program Business Wire
Sep-07-18 10:08AM  Why You Need To Look At This Factor Before Buying AmpliPhi Biosciences Corporation (NYSEMKT:APHB) Simply Wall St.
Aug-14-18 09:45AM  APHB: Meeting with the FDA Soon to Establish Path Forward for AB-SA01 and AB-PA01 Zacks Small Cap Research
Aug-09-18 06:50AM  AmpliPhi Biosciences Reports Second Quarter 2018 Financial Results and Business Highlights Business Wire
Jun-12-18 10:45AM  APHB: Successful Case Reports Presented for AB-SA01 and AB-PA01 Zacks Small Cap Research
Jun-07-18 04:15PM  AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Studies at American Society of Microbiology Annual Meeting Business Wire
08:00AM  AmpliPhi Biosciences Announces Presentation of AB-PA01 Bacteriophage Therapy Case Study at 41st European Cystic Fibrosis Conference Business Wire
May-25-18 11:53AM  Did AmpliPhi Biosciences Corporations (NYSEMKT:APHB) Earnings Growth Outperform The Industry? Simply Wall St.
May-18-18 06:50AM  AmpliPhi Biosciences to Present at 5th World Congress on Targeting Infectious Diseases: Targeting Phage & Antibiotic Resistance 2018 Business Wire
May-17-18 10:15AM  APHB: Case Study on AB-PA01 Presented at ISHLT Annual Meeting Zacks Small Cap Research
May-15-18 04:02PM  AmpliPhi Biosciences Reports First Quarter 2018 Financial Results and Business Highlights Business Wire +5.70%
May-14-18 12:03PM  AmpliPhi Biosciences Corporations (NYSEMKT:APHB) Shift From Loss To Profit Simply Wall St.
May-10-18 07:15AM  Free Technical Insights on Aimmune Therapeutics and Three More Biotech Stocks ACCESSWIRE
May-08-18 06:50AM  AmpliPhi Biosciences to Hold 2018 First Quarter and Business Update Conference Call on May 15 Business Wire
May-03-18 04:15PM  AmpliPhi Biosciences Will Utilize NIAID Preclinical Services to Advance Development of Its Targeted Therapeutic Candidate for the Treatment of Resistant Staphylococcus Aureus Business Wire
Apr-03-18 06:50AM  AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Study at ISHLT Annual Meeting Business Wire
Mar-26-18 10:30AM  APHB: Expecting to Meet with FDA in mid-2018 to Determine Regulatory Path Forward Zacks Small Cap Research
Mar-22-18 04:10PM  AmpliPhi Biosciences Announces Closing of Registered Direct Offering of Common Stock Business Wire -5.69%
Mar-20-18 08:00AM  AmpliPhi Biosciences Announces Registered Direct Offering of Common Stock Business Wire -21.43%
Mar-19-18 04:10PM  AmpliPhi to Collaborate with Western Sydney Local Health District and Westmead Institute for Medical Research on Expanded Access for Investigational Bacteriophage Therapeutics AB-SA01 and AB-PA01 Business Wire
Mar-14-18 04:10PM  AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2017 Financial Results and Business Highlights Business Wire
Mar-13-18 07:30AM  Wired News AmpliPhi Biosciences Presents Pre-Clinical Data Validating AB-PA01s Efficacy in Reducing Biofilm in Pseudomonas Aeruginosa Infections ACCESSWIRE
06:50AM  AmpliPhi to Collaborate with the U.S. Department of Veterans Affairs on Expanded Access for Investigational Bacteriophage Therapeutics AB-SA01 and AB-PA01 Business Wire
Mar-09-18 06:50AM  AmpliPhi Biosciences Announces Presentation of Preclinical Data Demonstrating that AB-PA01 Reduces Biofilm in Pseudomonas aeruginosa In Vivo Model Business Wire
Feb-20-18 11:02AM  Best AMEX Growth Companies Simply Wall St. +9.02%
Jan-20-18 11:02AM  Best High Growth AMEX Stocks This Week Simply Wall St.
Jan-10-18 06:00AM  AmpliPhi Biosciences Announces Pricing of $4.0 Million Public Offering of Common Stock Business Wire -25.33%
Jan-09-18 05:13PM  AmpliPhi Biosciences Announces Proposed Public Offering of Common Stock Business Wire -19.79%
Jan-05-18 11:00AM  APHB: Reports Positive Interim Results for Expanded Access Program Zacks Small Cap Research
Jan-03-18 04:05PM  AmpliPhi Biosciences Announces Positive Interim Results for Single-Patient Expanded Access Program Utilizing AB-SA01 and AB-PA01 Business Wire +10.89%
Jan-02-18 04:05PM  AmpliPhi Biosciences to Present at Biotech Showcase 2018 Business Wire
Dec-20-17 11:02AM  Best NasdaqGM Growth Stocks Simply Wall St.
Dec-14-17 04:10PM  AmpliPhi Biosciences Provides Corporate and Strategic Update Business Wire
Nov-29-17 08:25AM  AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube
Nov-28-17 06:50AM  AmpliPhi Biosciences to Present at LD Micro 10th Annual Main Event Business Wire
Nov-19-17 11:02AM  Top Growth Stocks in November Simply Wall St.
Nov-17-17 12:00PM  APHB: Six Patients Treated So Far With AB-SA01 and AB-PA01 Under Expanded Access Programs Zacks Small Cap Research
Nov-14-17 04:01PM  AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results and Business Highlights Business Wire -5.49%
Nov-08-17 04:05PM  AmpliPhi Biosciences to Hold 2017 Third Quarter and Business Update Conference Call on November 14 Business Wire
Oct-31-17 06:50AM  AmpliPhi Biosciences to Participate in the BIO-Europe 2017 Conference Business Wire
Oct-11-17 06:50AM  AmpliPhi Biosciences to Participate in Two Upcoming Conferences Business Wire
Oct-02-17 06:50AM  AmpliPhi Biosciences Announces Publication of Preclinical Data for AB-PA01 Showing Activity in Reducing Biofilms of Pseudomonas Aeruginosa Business Wire
Sep-18-17 06:50AM  AmpliPhi Biosciences CEO to Moderate Panel Discussion at Upcoming Anti-Infectives Rx Conference Business Wire
Sep-11-17 06:50AM  AmpliPhi Biosciences Announces First Intravenous Treatment of a Patient with AB-SA01 Targeting Staphylococcus aureus Business Wire
Sep-06-17 06:50AM  AmpliPhi Biosciences Announces Receipt of $2.0 Million R&D Tax Incentive Business Wire
Sep-05-17 06:50AM  AmpliPhi Biosciences to Present at Rodman & Renshaw 19th Annual Global Investment Conference Business Wire
Aug-23-17 11:00AM  APHB: Patient Treated Under Expanded Access Protocol With AB-PA01 Zacks Small Cap Research
Aug-21-17 06:50AM  AmpliPhi Biosciences Announces Publication of Bacteriophage Case Study for Life-Threatening Antibiotic-Resistant Infection Business Wire
Aug-16-17 11:30AM  AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017 Capital Cube
Aug-14-17 04:05PM  AmpliPhi Biosciences Reports Second Quarter 2017 Financial Results and Business Highlights Business Wire
01:00PM  Investor Network: AmpliPhi BioSciences Corporation to Host Earnings Call ACCESSWIRE
Aug-07-17 06:50AM  AmpliPhi Biosciences to Hold 2017 Second Quarter and Business Update Conference Call on August 14 Business Wire
Jul-10-17 08:00AM  AmpliPhi Biosciences Novel Approach to Treating Bacterial Infection Accesswire
Jul-05-17 06:50AM  AmpliPhi Biosciences to Present at Bacteriophage Therapy Workshop Sponsored by the FDA and NIH Business Wire +8.45%
Jun-28-17 05:00PM  APHB: New CEO to Lead New Strategic Focus Zacks Small Cap Research
Jun-14-17 06:50AM  AmpliPhi Biosciences Announces Presentation and Panel Participation at BIO International Convention Business Wire
May-31-17 04:05PM  AmpliPhi Biosciences Appoints Paul C. Grint, M.D. as Chief Executive Officer Business Wire
May-30-17 06:50AM  AmpliPhi Biosciences to Present at 7th Annual LD Micro Invitational Conference on June 6 Business Wire -6.88%
May-24-17 09:43AM  AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017 Capital Cube
May-19-17 11:30AM  APHB: Changing Focus to Developing Personalized Phage Therapies Zacks Small Cap Research +11.76%
May-15-17 04:01PM  AmpliPhi Biosciences Reports First Quarter 2017 Financial Results and Provides Business Highlights Business Wire
May-11-17 06:50AM  AmpliPhi Biosciences to Hold Business Update Conference Call on May 15 Business Wire
May-10-17 05:29PM  AmpliPhi Biosciences Announces Closing of Public Offering Business Wire
May-05-17 11:05AM  AmpliPhi Biosciences Crumbles After Announcing Secondary Offering 24/7 Wall St. -58.62%
May-04-17 10:02PM  AmpliPhi Biosciences Announces Pricing of $10.4 Million Underwritten Public Offering of Common Stock and Common Warrants Business Wire +62.92%
May-01-17 06:50AM  AmpliPhi Biosciences Announces a New Strategic Emphasis on Personalized Therapies for Serious or Life-Threatening Antibiotic-Resistant Infections Business Wire -8.68%
Apr-25-17 04:15PM  APHB: Looking to Follow-up on a Successful 2016 Zacks Small Cap Research -8.19%
06:50AM  AmpliPhi Biosciences Announces Presentation of Personalized Bacteriophage Therapy Case Study for Life-Threatening Antibiotic-Resistant Infection at Scientific Conference Business Wire
Apr-24-17 08:00AM  AmpliPhi Biosciences Review of Recent FDA Feedback and Drug Pipeline Accesswire +9.73%
Apr-17-17 09:00AM  AmpliPhi Biosciences Announces Positive Feedback from FDA on Phase 2 Development Proposal Business Wire
Apr-14-17 05:00PM  AmpliPhi Biosciences Announces Planned One-for-Ten Reverse Stock Split Business Wire
Apr-04-17 06:50AM  AmpliPhi Biosciences Announces Presentations of Clinical and Preclinical Data from Studies with its Bacteriophage Technology at Two Scientific Conferences Business Wire
06:50AM  AmpliPhi Biosciences Announces Presentations of Clinical and Preclinical Data from Studies with its Bacteriophage Technology at Two Scientific Conferences
Mar-31-17 01:04PM  AMPLIPHI BIOSCIENCES CORP Financials
Mar-29-17 12:54PM  AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017 Capital Cube -7.87%
12:54PM  AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017
10:24AM  AmpliPhi Biosciences Corp. :APHB-US: Earnings Analysis: 2016 By the Numbers : March 29, 2017
Mar-27-17 05:06PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:55PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 10-K, Annual Report
04:11PM  AmpliPhi Biosciences Reports 2016 Fourth-Quarter and Full-Year Results and Provides Corporate Highlights Business Wire
Mar-07-17 06:50AM  AmpliPhi Biosciences to Present at the 29th Annual ROTH Investor Conference Business Wire
Feb-23-17 06:50AM  AmpliPhi Biosciences Establishes Scientific Advisory Board and Appoints Dr. Timothy Lu of MIT and Broad Institute as SAB Chairman Business Wire
Feb-06-17 06:50AM  AmpliPhi Biosciences to Present at the 19th Annual BIO CEO and Investor Conference Business Wire -6.46%
Feb-02-17 04:16PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
Jan-30-17 06:50AM  AmpliPhi Biosciences Appoints Dr. Igor P. Bilinsky as Senior Vice President and Chief Operating Officer Business Wire
Jan-26-17 07:10AM  Research Reports Coverage on Biotech Stocks -- OncoGenex Pharma, INSYS Therapeutics, Threshold Pharma, and AmpliPhi Biosciences PR Newswire
Jan-09-17 08:32AM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure
Jan-04-17 08:45AM  Renowned Sinus Surgeon Dr. Peter-John Wormald Comments on AmpliPhi Biosciences Favorable Phase 1 Results of AB-SA01 in Chronic Rhinosinusitis Patients Business Wire
Dec-22-16 12:50PM  ETFs with exposure to AmpliPhi Biosciences Corp. : December 22, 2016
Dec-19-16 05:11PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Other Events
08:45AM  AmpliPhi Biosciences Reports Favorable Final Results From Phase 1 Trial of AB-SA01 in Chronic Rhinosinusitis Patients Business Wire
Dec-09-16 12:03PM  ETFs with exposure to AmpliPhi Biosciences Corp. : December 9, 2016 -8.25%
Dec-05-16 04:32PM  AMPLIPHI BIOSCIENCES CORP Files SEC form 8-K, Other Events
AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus infections; and AB-PA01 for the treatment of pseudomonas aeruginosa infections. AmpliPhi Biosciences Corporation has a collaboration agreement and a license agreement with the University of Leicester; and a collaboration agreement with the Western Sydney Local Health District and the Westmead Institute for Medical Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERRY MICHAEL SDirectorMar 22Buy1.10181,820200,002411,105Mar 26 08:51 PM
COOK JEREMY CURNOCKDirectorMar 22Buy1.10181,820200,002411,105Mar 26 08:50 PM